MENTOR Metabolic control of cell growth by mTOR in health and disease: a multi-disciplinary training
- Coordinator
- Universite Paris Cite, France
- Runs
- 1 January 2025 to 31 December 2028
- Status
- Running
- EU funding
- €4.0m
- Total cost
- —
- Partners
- 26 organisations in 11 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101168624
What the project is doing
In the project's own words, from its summary on CORDIS.
MENTOR is a multi-disciplinary training network which focuses on the mTOR pathway, a central mechanistic hub that integrates nutritional cues and controls cell growth and metabolism. Aberrant activation of mTOR underlies monogenic diseases with broad spectrum of pathological manifestations, including tissue overgrowth, polycystic kidneys and neuropsychiatric disorders affecting around two million of people worldwide. To avoid the medical errancy of patients in different clinical departments and surgical mutilations, approaches of personalized medicine depending on the genetic landscape need to be implemented, taking advantage of suitable pharmacological products.
The overall goal of the MENTOR research program is to: delineate molecular mechanisms of fundamental and aberrant mTOR functions, preclinically decipher the pathophysiology of mTOR, develop a novel arsenal of drugs to selectively target the pathway and provide proof-of-concept support for such interventions. This ambition can only be achieved by the multidisciplinary research program that MENTOR has conceived, through the training of a new generation of scientists at Graduate Schools of biology, pharmacy, chemistry or medicine that will become the leaders of mTOR research in both public and private sectors.
MENTOR will establish a collaborative and efficient network from academia to industry, involving patient associations and clinicians with impact on scientific community and society.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universite Paris Cite | Paris | France | Coordinator |
| Katholieke Universiteit Leuven | Leuven | Belgium | Participant |
| Topadur Pharma AG | Schlieren | Switzerland | Associatedpartner |
| Universitat Basel | Basel | Switzerland | Associatedpartner |
| Universite De Fribourg | Fribourg | Switzerland | Associatedpartner |
| Biosolveit GmbH | Sankt Augustin | Germany | Associatedpartner |
| Eberhard Karls Universitaet Tuebingen | Tuebingen | Germany | Participant |
| European Tuberous Sclerosis Complex Association (e-tsc) | Wiesbaden | Germany | Associatedpartner |
| Universitaetsklinikum Essen | Essen | Germany | Participant |
| Idryma Technologias Kai Erevnas | Irakleio | Greece | Participant |
| Panepistimio Ioanninon | Ioannina | Greece | Associatedpartner |
| Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii | Madrid | Spain | Participant |
| Universidad Autonoma De Madrid | Madrid | Spain | Associatedpartner |
| Assistance Publique Hopitaux De Paris | Paris | France | Associatedpartner |
| Institut Du Cerveau Et De La Moelle Epiniere | Paris | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Associatedpartner |
| Sorbonne Universite | Paris | France | Associatedpartner |
| Fondazione Telethon Ets | Roma | Italy | Participant |
| Universita Degli Studi Di Napoli Federico Ii | Napoli | Italy | Associatedpartner |
| Mimetas BV | Leiden | Netherlands | Participant |
| Pd-Value BV | Houten | Netherlands | Participant |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Participant |
| Miedzynarodowy Instytut Biologii Molekularnej I Komorkowej W Warszawie | Warszawa | Poland | Associatedpartner |
| Miedzynarodowy Instytut Mechanizmow I Maszyn Molekularnych Polskiej Akademii Nauk | Warszawa | Poland | Participant |
| The Myrovlytis Trust | London | United Kingdom | Associatedpartner |
| Cell Signaling Technology, Inc. | Danvers | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI